The patented aflo™ platform combines a medical device, user-centred app and a cloud-based data analytics hub, delivering automated inhaler technique training, remote clinical support and objective inhaler use evaluation.

An MHRA approved clinical investigation in 100 patients completed in 2024 demonstrated improved inhaler proficiency score (IPS), clinically significant improvements in symptom control (Asthma Control Test), Quality of Life (St George’s Respiratory Questionnaire) reduced reliever and healthcare usage.

A Harvard/Boston Children’s Hospital pilot study completed in 2026 showed improvements in IPS, symptom score and inflammatory markers (FeNO)

New pilot studies for children with severe asthma will commence in the EU and UK in 2026. Contact us to learn more.